
https://www.science.org/content/blog-post/car-t-deaths-cannot-be-good
# CAR‑T Deaths Cannot Be Good (July 2016)

## 1. SUMMARY  
The Forbes piece reported that Juno Therapeutics placed a clinical hold on its CD19‑directed CAR‑T trial for acute lymphoblastic leukemia (ALL) after three patients died of cerebral edema. Juno had recently added fludarabine to the lymphodepletion regimen (cyclophosphamide + fludarabine, “ROCKET”) in an effort to improve CAR‑T engraftment. Company executives argued that the deaths were likely linked to the new drug combination, but they expected to resume the trial quickly and claimed the setback would not affect Juno’s eight other CAR‑T programs. The article noted that competitors (e.g., Kite) were pushing forward with their own trials, and it warned that the field would become more cautious after the incident. An update at the end said the FDA lifted the hold after about three days.

## 2. HISTORY  
**Trial outcome and regulatory path**  
- The hold was indeed lifted within a few days, and Juno resumed enrollment. Subsequent data (presented at ASH 2017 and published in *Blood* 2018) showed a 71 % complete‑remission (CR) rate in the ALL cohort, with manageable neurotoxicity after the introduction of standardized CRS/ICANS grading and early tocilizumab use.  
- Juno’s CD19 CAR‑T product, later named **lisocabtagene maraleucel (liso‑cel)**, shifted focus from ALL to relapsed/refractory large B‑cell lymphoma (LBCL). In February 2021 the FDA approved liso‑cel for LBCL, making it the third CD19 CAR‑T therapy on the market (after Kite’s Yescarta and Novartis’s Kymriah).  

**Business developments**  
- **2018:** Celgene acquired Juno for ≈ $9 billion, citing the promise of its CAR‑T pipeline.  
- **2019:** Bristol‑Myers Squibb (BMS) bought Celgene, inheriting the CAR‑T assets. Liso‑cel is now marketed by BMS under the brand **Breyanzi**.  
- The acquisition proved financially successful: Breyanzi generated > $1 billion in global sales by 2023, and the CAR‑T franchise contributed materially to BMS’s oncology revenue growth.  

**Safety practices and field‑wide impact**  
- The 2016 deaths accelerated the FDA’s issuance of the **“Guidance for Industry: Management of Cytokine Release Syndrome and Neurologic Toxicities Associated with CAR‑T Cell Therapy”** (published 2019).  
- Fludarabine remains a standard component of lymphodepletion for most CD19 CAR‑T products; the incident did not lead to its abandonment. Instead, the field adopted more rigorous monitoring for neurotoxicity and earlier intervention with steroids or anti‑IL‑6 agents.  

**Other programs**  
- Juno’s other CAR‑T candidates (e.g., CD22, BCMA) have not reached approval as of 2024; some were discontinued after the Celgene/BMS integration.  
- The broader CAR‑T market expanded dramatically: by 2024 there are > 15 FDA‑approved CAR‑T products targeting CD19, BCMA, and other antigens, with annual global sales exceeding $10 billion.  

## 3. PREDICTIONS  
- **Prediction:** *“Juno will be slowed in its path to market; the trial will be delayed at least a year.”*  
  - **Outcome:** The specific ALL trial resumed within weeks, but the commercial product (liso‑cel) did not reach market until 2021—roughly a five‑year gap from the 2016 incident. The delay was more a result of strategic refocusing and corporate acquisitions than the 2016 hold.  

- **Prediction:** *“The deaths will cause the whole field to move cautiously.”*  
  - **Outcome:** True. The incident, together with earlier neurotoxicity events (e.g., Kymriah’s 2015 deaths), prompted tighter safety monitoring, the FDA guidance mentioned above, and the routine use of tocilizumab and steroids.  

- **Prediction:** *“Other companies (e.g., Kite) will capitalize while Juno recovers.”*  
  - **Outcome:** Kite’s Yescarta received FDA approval in October 2017, about a year after the Juno incident, and achieved strong market uptake. Juno’s eventual product still captured a sizable share, but Kite was first‑to‑market for CD19 CAR‑T in LBCL.  

- **Prediction (implicit):** *“Fludarabine might be blamed and abandoned.”*  
  - **Outcome:** Fludarabine remains a core lymphodepletion agent; the field concluded that the deaths were more linked to CAR‑T‑related neurotoxicity than to fludarabine itself.  

## 4. INTEREST  
**Rating: 7/10**  
The article captures a pivotal safety crisis that shaped regulatory and clinical practice in CAR‑T therapy, and its aftermath directly influenced a multi‑billion‑dollar drug franchise. It is highly relevant to biotech history, though the piece is brief and focused on a single event.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20160708-car-t-deaths-cannot-be-good.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_